Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Enspryng
Pharma
Roche's Enspryng cuts MOGAD relapse risk by 68% in phase 3
The "very impressive" phase 3 results set Enspryng up to become the first FDA-approved therapy for MOGAD, a rare autoimmune disorder.
Angus Liu
Apr 21, 2026 10:15am
Another setback for Enspryng as Roche halts Duchenne development
Feb 23, 2026 3:40pm
Enspryng falls short of Roche's expectations in myasthenia gravis
Mar 21, 2024 11:28am
#FierceMadness: ChemoCentryx beats BioMarin by major margin
Apr 6, 2022 3:00am
Roche wins European approval for subcutaneous NMOSD drug
Jun 29, 2021 8:55am
Roche's new approval Enspryng cuts relapse risk in NMOSD
Sep 10, 2020 9:43am
